Abstracts tagged "fibrosis and scleroderma"

Abstract Number: 116 • 2018 ACR/ARHP Annual Meeting
Identifying Matricellular Protein CYR61 As a Potential Anti-Fibrotic and Pro-Angiogenic Mediator in Scleroderma
Pei-Suen Tsou¹, Dinesh Khanna² and Amr H Sawalha¹, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, University of Michigan Scleroderma Program, Ann Arbor, MI
Background/Purpose: Vascular abnormalities represent a fundamental event in the pathogenesis of scleroderma (SSc) in that endothelial cell (EC) damage triggers a self-fueling process ending in…
Abstract Number: 131 • 2018 ACR/ARHP Annual Meeting
Myofibroblast Cells Expression of CD248 May Contribute to Exacerbate Microvascular Damage during Systemic Sclerosis
Paola Di Benedetto¹, Rebecca Ross², Paola Cipriani¹, Filomena Esteves³, Vasiliki Liakouli¹, Piero Ruscitti¹, Francesco Carubbi¹, Onorina Berardicurti¹, Noemi Panzera¹, Salvatore Di Bartolomeo¹, Chiara Galloni⁴, Georgia Mavria⁴, Francesco Del Galdo² and Roberto Giacomelli¹, ¹Department of Applied Clinical Sciences and Biotechnology, Rheumatology Unit, University of L'Aquila, L'Aquila, Italy, ²Leeds Biomedical Research Centre and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom, ⁴Signal Transduction and Tumour Microenvironment Group, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, Italy
Background/Purpose: Microvascular rarefaction and tissue fibrosis are the hallmarks of Systemic Sclerosis (SSc). CD248, also known as endosialin, is a transmembrane glycoprotein expressed on key…
Abstract Number: 1717 • 2018 ACR/ARHP Annual Meeting
Expert Consensus on the Screening, Treatment, and Management of Patients with Systemic Sclerosis-Interstitial Lung Disease, and the Potential Role of Anti-Fibrotics in a Treatment Paradigm for Systemic Sclerosis-Interstitial Lung Disease: A Delphi Consensus Study
Dinesh Khanna^1,2, Mary Strek³, Brian Southern⁴, Rajan Saggar⁵, Vivien Hsu⁶, Maureen D. Mayes⁷, Rick Silver⁸, Virginia D. Steen⁹, Donald Zoz¹⁰ and Franck Rahaghi¹¹, ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, University of Michigan, Ann Arbor, MI, ³Pulmonology, University of Chicago, Chicago, IL, ⁴Pulmonology, Cleveland Clinic Ohio, Cleavland, OH, ⁵Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁶Rheumatology, Robert Wood Johnson University Scleroderma Program, New Brunswick, NJ, ⁷Rheumatology, University of Texas Medical School at Houston, Houston, TX, ⁸Rheumatology, Medical University of SC, Charleston, SC, ⁹Dept of Rheumatology, Georgetown Univ Medical Center, Washington, DC, ¹⁰Pulmonology, Boehringer Ingelheim, Ridgefield, CT, ¹¹Cleveland Clinic Florida Weston, Weston, FL
Background/Purpose: Systemic sclerosis (SSc), or scleroderma, is a rare, autoimmune, multisystem connective tissue disorder characterized by vascular damage, autoimmunity, and fibrosis of the skin and…
Abstract Number: 767 • 2017 ACR/ARHP Annual Meeting
Elevated MeCP2 Expression in Diffuse Cutaneous Systemic Sclerosis Dermal Fibroblasts Is Associated with Anti-Fibrotic Effects
Ye He¹, Pei-Suen Tsou², Dinesh Khanna³ and Amr H Sawalha², ¹Rheumatology, University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, University of Michigan, Ann Arbor, MI, ³University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic Sclerosis (SSc) is a multisystem autoimmune connective tissue disorder characterized by vascular injury and fibrosis of the skin and internal organs. Methyl-CpG-binding protein…
Abstract Number: 776 • 2017 ACR/ARHP Annual Meeting
Circulating Fibrocytes in Systemic Sclerosis Patients and Healthy Subjects: An in Vitro Study
Maurizio Cutolo¹, Paola Montagna², Stefano Soldano², Amelia Chiara Trombetta³, Paola Contini⁴, Vanessa Smith⁵, Barbara Ruaro², Alberto Sulli³ and Renata Brizzolara², ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS A.O.U. San Martino-IST, University of Genova, Genoa, Italy, Genoa, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino, Genoa, Italy, Genoa, Italy, ³Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS A.O.U. San Martino-IST, University of Genova, Genoa, Italy, Genova, Italy, ⁴Division of Clinical Immunology, Department of Internal Medicine, University of Genova, Genoa, Italy, Genova, Italy, ⁵Faculty of Internal Medicine, Ghent University, Ghent, Belgium
Background/Purpose: Circulating fibrocytes seem to exert immunomodulatory effects, expressing class II major histocompatability complex molecules (HLA-DP, -DQ, and -DR) and could have a role in…
Abstract Number: 806 • 2016 ACR/ARHP Annual Meeting
Single Cell Rnaseq Defines a Unique Transcriptome Profile for Myofibroblasts in the Skin of Patients with Systemic Sclerosis
Robert A. Lafyatis¹, Lisa Rice², Giuseppina Stifano², Jeff Browning^2,3 and Robert W. Simms⁴, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ²Boston University School of Medicine, Boston, MA, ³Boston university, Cambridge, MA, ⁴Rheumatology, Boston University School of Medicine, Boston, MA
Background/Purpose: Fibrosis in systemic sclerosis (SSc), as well as a wide variety of other fibrotic diseases, is largely driven by myofibroblasts. Myofibroblasts are known to…
Abstract Number: 1855 • 2016 ACR/ARHP Annual Meeting
Phosphodiesterase-5 Inhibitors Attenuate Fibrotic Phenotype and Restore Anti-Fibrotic Resopnses of Cutaneous Fibroblasts in Patients with Scleroderma
Vikas Agarwal¹, Mohit kumar Rai¹, Vinita Agrawal², Harshit Singh¹ and Saurabh Chaturvedi¹, ¹Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Pathology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, India
Background/Purpose: Scleroderma (SSc) is a chronic autoimmune disease, characterized by excessive fibrosis of skin and internal organs due to uncontrolled proliferation of fibroblasts and deposition…
Abstract Number: 1856 • 2016 ACR/ARHP Annual Meeting
Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04755) As a Potential Topical Treatment for Scleroderma
Vishal Deshmukh¹, Allison Hood², Maureen Ibanez¹, Luis Dellamary¹, Josh Stewart¹, Timothy Seo¹, John Hood² and Yusuf Yazici¹, ¹Samumed, LLC, San Diego, CA, ²Samumed, LLC (formerly), San Diego, CA
Background/Purpose: Scleroderma is an autoimmune fibrotic disease, which presents skin manifestations among others. The Wnt pathway plays an important role in inflammation, skin fibrosis, and…
Abstract Number: 3264 • 2015 ACR/ARHP Annual Meeting
Multiplex Serum Protein Analysis in Systemic Sclerosis Defines Potential Anti-Fibrotic Mechanisms and Markers of Response to Hyperimmune Caprine Serum
Niamh Quillinan¹, Kristina E.N. Clark¹, Deirdre McIntosh², Jeffrey Vernes² and Christopher P. Denton³, ¹Rheumatology, UCL Division of Medicine, London, United Kingdom, ²Daval International, London, United Kingdom, ³Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom
Background/Purpose: Hyperimmune caprine serum (HICS) administered by subcutaneous injection over 26 weeks has shown benefit for modified Rodnan skin score in diffuse systemic sclerosis…
Abstract Number: 1796 • 2014 ACR/ARHP Annual Meeting
Autotaxin Is Highly Expressed in Systemic Sclerosis (SSc) Skin, Mediates Dermal Fibrosis Via IL-6, and Is a Target for SSc Therapy
Flavia V. Castelino^1,2, Leaya M. George³, Gretchen Bain⁴, Lance Goulet⁵, Robert Lafyatis⁶ and Andrew M. Tager^3,7, ¹Rheumatology, Massachusetts General Hospital, Boston, MA, ²Harvard Medical School, Boston, MA, ³Pulmonary Unit, Massachusetts General Hospital, Boston, MA, ⁴Biology, PharmAkea Pharmaceuticals, San Diego, CA, ⁵PharmAkea Pharmaceuticals, San Diego, CA, ⁶Rheumatology, Boston University School of Medicine, Boston, MA, ⁷Massachusetts General Hospital, Boston, MA
Background/Purpose Autotaxin (ATX) is an enzyme present in biological fluids that is responsible for the production of the lipid mediator, lysophosphatidic acid (LPA). We previously…
Abstract Number: 1725 • 2014 ACR/ARHP Annual Meeting
The SYK Inhibitor Fostamatinib Limits Tissue Damage and Fibrosis in a Bleomycin-Induced Scleroderma MOUSE MODEL
Omer Nuri Pamuk¹, Guray Can², Suleyman Ayvaz³, Turan Karaca⁴, Gulsum Pamuk⁵, Selim Demirtas⁶ and George C. Tsokos⁷, ¹Rheumatology, Trakya University Medical Faculty, Edirne, Turkey, ²Gastroenterology, Trakya University Medical Faculty, Edirne, Turkey, ³Pediatric Surgery, Trakya University Medical Faculty, Edirne, Turkey, ⁴Histology, Trakya University Medical Faculty, Edirne, Turkey, ⁵Hematology, Trakya University Medical Faculty, Edirne, Turkey, ⁶Trakya University Medical Faculty, Edirne, Turkey, ⁷Rheumatology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA
Background/Purpose The possible antifibrotic effects of various kinase inhibitors has been studied before in SSc. Spleen tyrosine kinase (Syk) is a protein tyrosine kinase which…
Abstract Number: 969 • 2014 ACR/ARHP Annual Meeting
Caspase-8 Prevents Lung Fibrosis in a Murine SSc-like Disease Model By Preventing Macrophage Differentiation
Alexander Misharin¹, Carla M. Cuda², Luisa Morales-Nebreda³, Gokhan Mutlu¹, GR Scott Budinger³ and Harris R. Perlman⁴, ¹Northwestern University, Chicago, IL, ²Medicine / Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose Pulmonary fibrosis has emerged as the leading cause of death in patients with Systemic Sclerosis (SSc). Currently available therapies are only marginally effective in…
Abstract Number: 964 • 2014 ACR/ARHP Annual Meeting
Skin Collagen Synthesis Rates Distinguish Between Early and Late Diffuse Scleroderma Patients
Claire Emson¹, Martin Decaris¹, Michelle Gatmaitan¹, Flora Luo¹, Dan Holochwost¹, Simplicia FloraCruz¹, Thomas Angel¹, Kelvin Li¹, Marc Hellerstein¹, Fredrick M. Wigley², Scott Turner^1,3 and Francesco Boin², ¹KineMed Inc., Emeryville, CA, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³5980 Horton Street, Suite 470, KineMed Inc., Emeryville, CA
Background/Purpose The synthesis and degradation of extracellular matrix (ECM), particularly collagen, is one of the central mechanisms perturbed in scleroderma (SSc). Understanding the kinetics of…
Abstract Number: 771 • 2014 ACR/ARHP Annual Meeting
Development of a Bifluorescent Lineage Tracker Reporter Mouse Strain to Analyze the Phenotypic Conversion of Endothelial Cells into Myofibroblasts in Vivo. Application to Study the Synergistic Effects of Endothelin-1 on TGF-β1-Induced Endothelial-to-Mesenchymal Transition
Peter J. Wermuth and Sergio A. Jimenez, Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center,Thomas Jefferson University, Philadelphia, PA
Background/Purpose: Endothelial-to-mesenchymal transition (EndoMT) may be a crucial pathway in generating activated myofibroblasts, cells that play a pivotal role in the development of tissue and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].